ATE358489T1 - Verwendung von 7alpha-hydroxy-estradiol, 7alpha- hydroxy-dehydroepiandrosteron and 7alpha-hydroxy- pregnenolon derivaten zur behandlung der akuten zellulären degeneration - Google Patents
Verwendung von 7alpha-hydroxy-estradiol, 7alpha- hydroxy-dehydroepiandrosteron and 7alpha-hydroxy- pregnenolon derivaten zur behandlung der akuten zellulären degenerationInfo
- Publication number
- ATE358489T1 ATE358489T1 AT01905886T AT01905886T ATE358489T1 AT E358489 T1 ATE358489 T1 AT E358489T1 AT 01905886 T AT01905886 T AT 01905886T AT 01905886 T AT01905886 T AT 01905886T AT E358489 T1 ATE358489 T1 AT E358489T1
- Authority
- AT
- Austria
- Prior art keywords
- 7alpha
- hydroxy
- dehydroepiandrosterone
- estradiol
- treatment
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 title abstract 2
- OLPSAOWBSPXZEA-JIEICEMKSA-N 7alpha-hydroxydehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3[C@H](O)C=C21 OLPSAOWBSPXZEA-JIEICEMKSA-N 0.000 title 1
- CQPNIWHVQNCXHA-HTPGKPQGSA-N 7alpha-hydroxyestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](O)CC2=C1 CQPNIWHVQNCXHA-HTPGKPQGSA-N 0.000 title 1
- UEWNVBNIVGLQPG-XXHSLLPRSA-N 7alpha-hydroxypregnenolone Chemical class C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 UEWNVBNIVGLQPG-XXHSLLPRSA-N 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000007850 degeneration Effects 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002159 estradiols Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003132 pregnenolones Chemical class 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003524.6A GB0003524D0 (en) | 2000-02-15 | 2000-02-15 | Cytoprotective steroids (II) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE358489T1 true ATE358489T1 (de) | 2007-04-15 |
Family
ID=9885683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01905886T ATE358489T1 (de) | 2000-02-15 | 2001-02-15 | Verwendung von 7alpha-hydroxy-estradiol, 7alpha- hydroxy-dehydroepiandrosteron and 7alpha-hydroxy- pregnenolon derivaten zur behandlung der akuten zellulären degeneration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030092692A1 (de) |
| EP (1) | EP1307205B1 (de) |
| JP (1) | JP2003522794A (de) |
| AT (1) | ATE358489T1 (de) |
| AU (2) | AU2001233856B2 (de) |
| CA (1) | CA2398706A1 (de) |
| DE (1) | DE60127683D1 (de) |
| GB (1) | GB0003524D0 (de) |
| WO (1) | WO2001060375A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| US8124598B2 (en) | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
| HRP20120687T1 (hr) * | 2006-11-30 | 2012-09-30 | Hunter-Fleming Limited | Moduliranje metabolizma prostaglandina/ciklooksigenaze |
| US20100160274A1 (en) * | 2007-09-07 | 2010-06-24 | Sharon Sageman | 7-KETO DHEA for Psychiatric Use |
| CZ2008434A3 (cs) * | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| CU20110244A7 (es) | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU243975A (en) * | 1974-10-14 | 1982-06-30 | Schering Ag | Process for obtaining 7-hydroxyestradiols |
| US5292730A (en) * | 1990-08-29 | 1994-03-08 | Humanetics Corporation | Modulation of immune system with Δ5-androstenes |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5846963A (en) * | 1995-06-07 | 1998-12-08 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| EP0840612A1 (de) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate |
| NZ331975A (en) * | 1996-04-09 | 2000-12-22 | Btg Int Ltd | Use of 7 alpha-substituted steroids to treat neuropsychriatic disorders or enhance cognition |
| FR2760362B1 (fr) * | 1997-03-10 | 2000-08-11 | Vitasterol | Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles |
-
2000
- 2000-02-15 GB GBGB0003524.6A patent/GB0003524D0/en not_active Ceased
-
2001
- 2001-02-15 AT AT01905886T patent/ATE358489T1/de not_active IP Right Cessation
- 2001-02-15 JP JP2001559471A patent/JP2003522794A/ja active Pending
- 2001-02-15 WO PCT/GB2001/000627 patent/WO2001060375A2/en not_active Ceased
- 2001-02-15 DE DE60127683T patent/DE60127683D1/de not_active Expired - Lifetime
- 2001-02-15 EP EP01905886A patent/EP1307205B1/de not_active Expired - Lifetime
- 2001-02-15 AU AU2001233856A patent/AU2001233856B2/en not_active Ceased
- 2001-02-15 AU AU3385601A patent/AU3385601A/xx active Pending
- 2001-02-15 CA CA002398706A patent/CA2398706A1/en not_active Abandoned
- 2001-02-15 US US10/203,880 patent/US20030092692A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001233856B2 (en) | 2006-05-25 |
| WO2001060375A8 (en) | 2001-11-15 |
| WO2001060375A3 (en) | 2002-04-04 |
| JP2003522794A (ja) | 2003-07-29 |
| GB0003524D0 (en) | 2000-04-05 |
| DE60127683D1 (de) | 2007-05-16 |
| CA2398706A1 (en) | 2001-08-23 |
| EP1307205A2 (de) | 2003-05-07 |
| US20030092692A1 (en) | 2003-05-15 |
| EP1307205B1 (de) | 2007-04-04 |
| WO2001060375A2 (en) | 2001-08-23 |
| AU3385601A (en) | 2001-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| SG161307A1 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
| DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE478671T1 (de) | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DE60320770D1 (de) | Verfahren zur verabreichung von buprenorphin zur behandlung von depression | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| DE69413829D1 (de) | Antiglucocorticoidsteroide zur behandlung von angststörungen | |
| DE60127683D1 (de) | Verwendung von 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosteron and 7alpha-hydroxy-pregnenolon derivaten zur behandlung der akuten zellulären degeneration | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| ATE252897T1 (de) | Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen | |
| ATE406897T1 (de) | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs | |
| DE69825279D1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| ATE357912T1 (de) | Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE50008032D1 (de) | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen | |
| MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
| ATE321045T1 (de) | Methoden und zusammensetzungen zur behandlung von schmerzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |